Other Events ·
On June 17, 2026, Protagonist Therapeutics, Inc. held its Annual Meeting of Stockholders, where shareholders approved…
PTGXProtagonist Therapeutics, Inc
On June 17, 2026, Protagonist Therapeutics, Inc. held its Annual Meeting of Stockholders, where shareholders approved the adoption of the 2026 Equity Incentive Plan. This new plan replaces the 2016 Equity Incentive Plan and authorizes the issuance of 650,000 new shares plus any remaining shares from the 2016 plan and forfeited or expired awards. Stockholders also elected Class I directors Dinesh V. Patel and Lewis T. Williams, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis. The company is a biopharmaceutical company that develops therapies for inflammatory and autoimmune diseases.